Cancer Chemotherapy in Advanced Malignant Disease: A cost benefit analysis

Abstract

A cost benefit analysis of chemotherapy [vincristine, adriamycin, cyclophosphamide, methotrexate, citrovorum factor rescue] in unselected patients with advanced malignant disease originating in a defined population (250,000 inhabitants) demonstrated that the use of this therapy as the main treatment in hospitalized patients increased from a few percent during 1973 to 60% during 1977, corresponding to an increase in the cost of drugs from 10,000-200,000 dollars. At the same time the capacity for hospital care of patients with advanced malignancies increased from 317 to 488 patients without any enlargement of other resources. As more than 90 percent of the medical budget consists of expenditures for salaries and localities, a cheaper medical care was obtained, but, above all, the survival rate and the quality of life for many patients was improved.